Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
Either male or female adult patients (>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography
Pregnant and/or lactating women
Excessive alcohol use (defined as an average alcohol intake > 30 g per day in men and > 20 g per day in women)
Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.
patients suffering from chronic kidney disease, and hyper/hypoparathyroidism
Parallel
Carbocysteine 375 MG
DrugCarbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders
Physical activity, walking, and calorie restriction
Other intervention• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients
The change in the degree of steatosis in the Ultra Sound
The change in the degree of steatosis in the Ultra Sound
Click on the lead sponsor to view all of their trials.
